In January 2018, Professor Claudio de Simone published a paper in the journal “Clinical Gastroenterology and Hepatology” in which he sent a warning about many of the commercial probiotics on the market. In the paper, entitled “The unregulated probiotic market”, Professor de Simone, who is an internationally recognised leader in the field of probiotics and the human gut microflora, stated:
“Many properties of probiotics are strain-specific, and safety and efficacy findings associated to specific formulations should not be generalised to other probiotic products.” This is crucial, because we at Bioxyne Limited know that not all probiotics provide a health benefit. We have undertaken several clinical studies to show that the specific strain in Progastrim®, PCC®, is highly effective at boosting gut and immune health.
Professor de Simone went on to say: “Manufacturing processes, conditions and ingredients are important determinants of product characteristics and changes to manufacturing are likely to give rise to a product not identical to the "original" in efficacy and safety if proper measures and controls are not taken.”
Bioxyne’s probiotic products are manufactured to the highest standards by world-leading probiotic manufacturer Chr Hansn, based in Denmark. This ensures that each batch of PCC® is the same consistent quality.
Professor de Simone concluded: “These regulatory deficits may have serious consequences for patients where probiotics are used as part of clinical guideline-recommended management of serious conditions such as inflammatory bowel diseases, and may make doctors liable for prescribing a formulation not previously tested for safety and efficacy.”
Bioxyne’s dedication to clinical studies, manufacturing stringency and quality control ensures that consumers, patients and doctors alike can be confident that Progastrim®, does what it says it does in boosting gut and immune health.
de Simone C. Clin Gastroenterol Hepatol. 2018 Jan 25. pii: S1542-3565 (18) 30084-3. doi: 10.1016/j.cgh.2018.01.018.